BioCentury
ARTICLE | Deals

Lineage deal bolsters Roche’s ophthalmology pipeline as Lucentis biosimilars loom

Deal with Genentech allows Lineage to stick to core areas, cancer, spinal injury 

December 21, 2021 2:51 AM UTC

Through a deal with Lineage, Genentech has added another ophthalmology program to its pipeline with another new modality, shoring up its eye disease franchise in the face of biosimilar competition for Lucentis.

That program is OpRegen — a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted sub-retinally being investigated by Carlsbad, Calif.-based Lineage Cell Therapeutics Inc. (NYSE-A:LCTX) in patients with advanced dry age-related macular degeneration (MD) with geographic atrophy (GA). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article